Alphamab Oncology disclosed that it bought back 56,000 ordinary shares on 5 November 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were repurchased at prices ranging between HKD 6.39 and HKD 6.60, with a volume-weighted average cost of HKD 6.55 per share. The outlay totalled HKD 0.37 million.

Following the transaction, the company’s outstanding share count fell marginally by 0.0058% to 965.71 million shares, while treasury shares rose to 8.68 million. Total issued share capital remains unchanged at 974.38 million shares because the repurchased stock has been retained as treasury shares rather than cancelled.

The purchase was executed under the general mandate granted on 12 June 2026, which authorises Alphamab Oncology to repurchase up to 96.85 million shares. Including the latest transaction, the company has repurchased 2.80 million shares under this mandate to date, representing 0.29% of the issued shares outstanding when the authority was approved.

In line with Hong Kong listing rules, Alphamab Oncology is subject to a moratorium on issuing new shares or disposing of treasury shares until 5 December 2026.